Prostate cancer screening: Clinical impact of WHO calibration of Beckman Coulter Access® prostate-specific antigen assays

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 2, 2010, Pages 285-288

  Fillée, Catherine ^a   Tombal, Bertrand ^a   Philippe, Marianne ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Free prostate specific antigen (PSA); Prostate cancer; Total PSA; WHO calibration

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CALIBRATION; CALIBRATOR; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SIMULATION; WORLD HEALTH ORGANIZATION;

CALIBRATION; CLINICAL LABORATORY TECHNIQUES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 76649119781     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.039     Document Type: Article

References (25)

1. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306.
2. Schröder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels -3.0 ng/mL? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008;53:901-908
3. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc 1998;279:1542-1547
4. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006;52:1568-1574
5. Roddam AW, Rimmer J, Nickerson C, Ward AM. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006;43:35-48.
6. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 1996;48:10-15
7. Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000;86:590-597
8. Roddam AW, Price CP, Allen NE, Ward AM. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 2004;50:1012-1016
9. Stephan C, Kramer J, Meyer HA, Kristiansen G, Ziemer S, Deger S, et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007;99:1427-1431
10. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001;88:545-550
11. Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry. Clin Biochem 1998;31:475-481
12. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 2000;46:1310-1317
13. Chan DW, Sokoll LJ. WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies? Clin Chem 2000;46:1291-1292
14. Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, et al. A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer. Clin Chem Lab Med 2003;41:90-94
15. Semjonow A, Oberpenning F, Weining C, Schon M, Brandt B, De Angelis G, et al. Do modifications of non-equimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem 2001;47:1472-1475
16. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate- specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52:59-64.
17. Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schroder FH, van der Kwast TH. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 2005;103:708-716
18. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005; 165:1857-1861
19. Schröder FH, Bangma CH, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53:468-477
20. Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 2007;99:1296-1303
21. Stephan C, Kahrs AM, Klotzek S, Reiche J, Muller C, Lein M, et al. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med 2008;46:623-629
22. Sley PR, La'ulu SL, Roberts WL. International differences in results for total PSA, free PSA and percentage of free PSA. Am J Clin Pathol 2008;129:952-958
23. Vignati G, Giovanelli L. Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA. Int J Biol Markers 2007;22:295-301.
24. Jansen F, Roobol M, Bangma C, van Schaik R. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detections. Clin Chem 2008;54:1999-2006.
25. Stephan C, Bangma C, Vignati G, Barstch G, Lein M, Jung K, et al. 20-25% lower concentrations of total and free prostate specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers. Int J Biol Markers 2009;24:65-69